Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective study to assess the burden of existing or hidden cardiovascular (CV) and renal disease in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a Hong Kong public hospital setting. By implementing a chronic obstructive pulmonary disease (COPD) discharge care bundle with integrated CV/renal screening, the study aims to quantify undiscovered disease prevalence, evaluate risk factors for future exacerbations, and compare re-admission rates against historical controls, ultimately informing integrated cardiopulmonary management strategies.
Chronic obstructive pulmonary disease (COPD) is a major global health concern, characterized by persistent respiratory symptoms and airflow limitation, and it frequently coexists with cardiovascular disease (CVD), which significantly contributes to morbidity and mortality in this population.
This is a prospective study to assess the burden of existing or hidden cardiovascular (CV) and renal disease in patients with acute exacerbation of COPD (AECOPD) in a Hong Kong public hospital setting. By implementing a COPD discharge care bundle with integrated CV/renal screening, the study aims to quantify undiscovered disease prevalence, evaluate risk factors for future exacerbations, and compare re-admission rates against historical controls, ultimately informing integrated cardiopulmonary management strategies.
The objectives and hypotheses are as follows:
Objectives and Hypotheses Primary Objective To describe the prevalence of undiscovered cardiovascular and renal disease burden among patients hospitalized for AECOPD in a Hong Kong public clinical setting.
• Hypothesis: A significant proportion of AECOPD patients will have previously undiagnosed CV or renal diseases identified through proactive screening, highlighting the need for routine assessments.
Secondary Objectives
Exploratory Objectives
The COPD discharge care bundle includes:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Implementation of the COPD discharge care bundle | Experimental | Prospective recruitment with implementation of the COPD discharge care bundle |
|
| Historic controls | Other | Historical records of prior acute exacerbation of COPD episodes and management under standard care from the database |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intervention Group | Procedure | Implementation of a COPD discharge care bundle for multidisciplinary support, providing optimal care for patients following acute exacerbations during hospital discharge. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients observed to have different high-risk factors for future COPD exacerbation | Percentage of patients observed to have different high-risk factors for future COPD exacerbation | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Re-admission rate | Re-admission rate due to COPD/cardiovascular/renal-related causes | 12 months |
| Major Adverse Cardiac Events (MACE) | Major Adverse Cardiac Events (MACE), defined as myocardial infarction, stroke, death due to cardiovascular events, heart failure, arrhythmias, target vessel revascularization (e.g., repeat angioplasty), unscheduled coronary revascularization and cardiac arrest, will also be assessed. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Fanny WS Ko, MD | Contact | 85235053133 | fannyko@cuhk.edu.hk | |
| David SC Hui, MD | Contact | 85235053128 | dschui@cuhk.edu.hk |
| Name | Affiliation | Role |
|---|---|---|
| David SC Hui, MD | Chinese University of Hong Kong | Study Director |
Not provided
Data sharing is available to qualified investigators upon reasonable request. Interested parties should submit a proposal outlining the intended use of the data. Requests will be evaluated for scientific merit and alignment with ethical guidelines. Approved data will be transferred through secure, encrypted channels under a formal data-sharing agreement.
From 17 Jan 2026 to 17 Jan 2046
The principal investigator will access the IPD and supporting information.
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Patients with identified CV diseases will exhibit higher-risk profiles (e.g., elevated BMI, severe symptoms, frequent prior exacerbations), and the implementation of the care bundle will reduce re-admission rates compared to historical standard care
Not provided
Not provided
Not provided
Not provided
| Usual Care | Procedure | Patient undergoing usual care from historic controls |
|
| 12 months |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |